[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352072-105":59,"doc-detail-352072-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","estimating-lead-time-and-overdiagnosis-in-cancer-screening-programmes-the-mocci-method","Estimating lead time and overdiagnosis in cancer screening programmes - the MOCCI method","","Cancer screening supports earlier cancer detection and treatment, but key quantities such as lead time and overdiagnosis determine programme value. Lead time is defined as the interval between screening diagnosis and hypothetical symptomatic detection without screening, while overdiagnosis reflects tumours that would never become clinically apparent. The study develops MOCCI to estimate the lead time distribution and overdiagnosis probability using invited versus non-invited incidence, applied to the Slovenian breast screening programme.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/estimating-lead-time-and-overdiagnosis-in-cancer-screening-programmes-the-mocci-method/352072/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/estimating-lead-time-and-overdiagnosis-in-cancer-screening-programmes-the-mocci-method/352072.png","ImageObject",300,407,{"name":92,"@type":93},"nayy☆","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What do lead time and overdiagnosis mean in cancer screening programmes?","Question",{"text":113,"@type":114},"Lead time is the interval between a screen diagnosis and the hypothetical symptomatic detection without screening. Overdiagnosis refers to cases where a tumour detected by screening would never surface clinically.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the MOCCI method estimate lead time distribution and overdiagnosis probability?",{"text":118,"@type":114},"MOCCI compares age- and calendar-stratified cancer incidence between individuals invited to screening and those not invited, selecting a lead time distribution that minimizes incidence differences. It then estimates overdiagnosis by contrasting model-predicted lead time with time to death from other causes.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the main findings from the Slovenian breast cancer screening programme application?",{"text":122,"@type":114},"The study estimated that 30% (95% CI: 20% to 39%) of screen-detected cases were non-progressive and 33% (95% CI: 25% to 43%) were overdiagnosed. Under an exponential lead time distribution for progressive cancers, the mean lead time was 1.8 years (95% CI: 1.3 to 2.9).","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352072,1790482400,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":46,"preview_page_count":19,"preview_urls":145},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Estimating lead time and overdiagnosis in cancer screening programmes: the MOCCI method  \nBor Vratanar1,*,  and Maja Pohar Perme1  \n1 Institute for Biostatistics and Medical Informatics, University of Ljubljana, Ljubljana, Slovenia  \n*Corresponding author. Institute for Biostatistics and Medical Informatics, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia. E-mail: [bor.vratanar@mf.uni-lj.si](bor.vratanar@mf.uni-lj.si)  \nAbstract  \nBackground: Cancer screening enables earlier cancer diagnosis and treatment. The interval between cancer diagnosis by screening and the symptomatic detection in the absence of screening is termed lead time. If a patient’s tumour, detected by screening, would never surface clinically, the patient is considered overdiagnosed. Estimating these quantities is crucial for evaluating cancer screening programmes.  \nDevelopment: We developed MOCCI (Minimizing Observed and Counterfactual Cancer Incidence), a novel parametric method for estimating the lead time distribution. MOCCI compares age-and calendar-stratified cancer incidence between individuals invited to screening and those not invited and estimates the lead time distribution that minimizes the incidence difference between the two groups. The probability of overdiagnosis is then estimated by comparing the model-predicted lead time with the time to death from other causes.  \nApplication: In an application to the Slovenian breast cancer screening programme, we estimated that 30%(95% confidence interval [CI], 20% to 39%) of screen-detected cases were non-progressive and 33%(95% CI, 25% to 43%) were overdiagnosed; assuming an exponential lead time distribution for progressive cancers, the mean lead time was 1.8years (95% CI, 1.3 to 2.9).  \nConclusions: This study proposes a new method for estimating lead time and overdiagnosis. The proposed method (a) can accommodate various lead time distributions,(b) yields a lead time distribution that is aligned with the observed excess incidence arising from screening, and (c) enables the separation of different sources of overdiagnosis. The method provides stable estimates when sample sizes are large and the assumed lead time model is simple.  \nKeywords lead time, overdiagnosis, counterfactual, deconvolution, causal inference, incidence  \nKey Messages  \n· We present a new parametric method for estimating the lead time distribution and the probability of overdiagnosis in cancer screening programmes.  \n· The proposed method provided a good fit to real-world data; when applied to the Slovenian breast cancer screening programme, the estimated probability of overdiagnosis was 33%(95% confidence interval [CI], 25% to 43%), and the mean lead time among progressive screen-detected cases was 1.8 years (95% CI, 1.3 to 2.9) .  \n· The method enables separate estimation of overdiagnosis arising from non-progressive cancers and from progressive cancers that would not otherwise have been clinically diagnosed during a person’s lifetime.  \nIntroduction  \nIn cancer screening programmes, participants are screened every few years with medical tests to detect and treat cancer early, before symptoms appear. Individuals invited to participate in screening may remain cancer-free (no cancer cases), have their cancer detected by a screening test (screen-detected cases), or  \nbe diagnosed with cancer based on symptoms (symptomatic cases) . Symptomatic cases include cancers diagnosed between scheduled screenings (interval cancers) or among individuals who do not attend the screening programme.  \nLead time is commonly defined as the interval between a screen diagnosis and the hypothetical symptomatic (clinical) detection of cancer in the absence of screening. If lead time  \nReceived: 30 December 2025. Accepted: 7 July 2026  \n© The Author(s) 2026. Published by Oxford University Press on behalf of the International Epidemiological Association. This is an Open Access article distributed under the terms of the Creative Commons Attri","cbCaiaJXmLq3GF5Y","https://ap.wps.com/l/cbCaiaJXmLq3GF5Y","pdf",1240050,"English","# Abstract\n## Background\n## Development\n## Application\n## Conclusions\n# Key Messages\n# Introduction","[{\"question\":\"What do lead time and overdiagnosis mean in cancer screening programmes?\",\"answer\":\"Lead time is the interval between a screen diagnosis and the hypothetical symptomatic detection without screening. Overdiagnosis refers to cases where a tumour detected by screening would never surface clinically.\"},{\"question\":\"How does the MOCCI method estimate lead time distribution and overdiagnosis probability?\",\"answer\":\"MOCCI compares age- and calendar-stratified cancer incidence between individuals invited to screening and those not invited, selecting a lead time distribution that minimizes incidence differences. It then estimates overdiagnosis by contrasting model-predicted lead time with time to death from other causes.\"},{\"question\":\"What were the main findings from the Slovenian breast cancer screening programme application?\",\"answer\":\"The study estimated that 30% (95% CI: 20% to 39%) of screen-detected cases were non-progressive and 33% (95% CI: 25% to 43%) were overdiagnosed. Under an exponential lead time distribution for progressive cancers, the mean lead time was 1.8 years (95% CI: 1.3 to 2.9).\"}]","Estimating lead time and overdiagnosis in cancer screening programmes - the MOCCI method | PDF",1790097555,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/526e420ba842ff33b77fc010828d6a83.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b16e7ec2a2fd2f55a817fc607cccec32.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e4895f676437ee951a611c5533dddb5.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9413721a0dbb8308857ec9d9a426e47.webp",980,1287]